[go: up one dir, main page]

US20130197031A1 - Deuterated analogs of pridopidine useful as dopaminergic stabilizers - Google Patents

Deuterated analogs of pridopidine useful as dopaminergic stabilizers Download PDF

Info

Publication number
US20130197031A1
US20130197031A1 US13/820,024 US201113820024A US2013197031A1 US 20130197031 A1 US20130197031 A1 US 20130197031A1 US 201113820024 A US201113820024 A US 201113820024A US 2013197031 A1 US2013197031 A1 US 2013197031A1
Authority
US
United States
Prior art keywords
pharmaceutically acceptable
deuterium
acceptable salt
deuterated analog
represent hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/820,024
Inventor
Clas Sonesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals International GmbH
NSAB Filial af Neurosearch Sweden AB
Original Assignee
Ivax International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax International GmbH filed Critical Ivax International GmbH
Assigned to IVAX International GmbH reassignment IVAX International GmbH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE
Assigned to IVAX International GmbH reassignment IVAX International GmbH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE
Assigned to NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE reassignment NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SONESSON, CLAS
Publication of US20130197031A1 publication Critical patent/US20130197031A1/en
Assigned to TEVA PHARMACEUTICALS INTERNATIONAL GMBH reassignment TEVA PHARMACEUTICALS INTERNATIONAL GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: IVAX International GmbH
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Definitions

  • the present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine.
  • Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease.
  • the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.
  • Deuterium also called “heavy hydrogen” is a stable isotope of hydrogen with a natural abundance in the oceans of Earth of approximately one atom in 6,500 of hydrogen ( ⁇ 154 ppm). Deuterium thus accounts for approximately 0.0154% (alternately, on a mass basis: 0.0308%) of all naturally occurring hydrogen in the oceans on Earth.
  • the nucleus of deuterium called a deuteron, contains one proton and one neutron, whereas the hydrogen nucleus contains no neutron.
  • Deuterium forms bonds with carbon that vibrate at a lower frequency and are thus stronger than C—H bonds. Therefore “heavy hydrogen” versions of drugs may be more stable towards degradation and last longer in the organism. Incorporating deuterium in place of hydrogen thus may improve the pharmacodynamic and pharmacokinetic profiles of drugs, thus modifying the metabolic fate, while retaining the pharmacologic activity and selectivity of physiologically active compounds. Deuterated drugs thus may positively impact safety, efficacy and/or tolerability.
  • Pridopidine i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine, a dopaminergic stabilizer currently in clinical development for the treatment of Huntington's disease.
  • the compound is described in e.g. WO 01/46145, and in e.g. WO 2006/040155 an alternative method for its synthesis is described.
  • the object of the present invention is to provide analogs of Pridopidine with improved pharmacodynamic and pharmacokinetic profiles.
  • the invention provides a partially or fully deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine as represented by Formula 1, below.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine of the invention, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention relates to the use of the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine of the invention as a medicament, or for the manufacture of a medicament.
  • the invention provides a method for treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine according to the invention, or a pharmaceutically acceptable salt thereof.
  • the present invention provides deuterated analogs of Pridopidine.
  • the deuterated analog of the invention may be a fully or partially deuterium substituted derivative.
  • the deuterated analog of the invention may in particular be characterised by Formula I
  • R 1 -R 23 represents deuterium (D).
  • R 1 -R 23 represent hydrogen (H).
  • the abundance of deuterium at that position is at least 3340 times greater (i.e. at least 50.1% incorporation of deuterium) than the natural abundance of deuterium.
  • the abundance of deuterium at that position is at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 1 -R 2 represent deuterium (D);
  • R 3 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 1 -R 7 represents deuterium (D).
  • R 1 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 1 -R 7 represent deuterium (D).
  • R 8 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 8 , R 9 , R 10 and R 11 represent deuterium (D);
  • R 1 -R 7 and R 12 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 12 represents deuterium (D).
  • R 1 -R 11 and R 13 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R 17 -R 20 represent deuterium (D).
  • R 1 -R 16 and R 21 -R 23 represent hydrogen (H).
  • the deuterated analog of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the deuterated analog of the invention.
  • salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like.
  • Such salts may be formed by procedures well known and described in the art.
  • acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a deuterated analog of the invention and its pharmaceutically acceptable acid addition salt.
  • Examples of pharmaceutically acceptable cationic salts of a deuterated analog of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a deuterated analog of the invention containing an anionic group.
  • Such cationic salts may be formed by procedures well known and described in the art.
  • the deuterated analog of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like.
  • Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • the deuterated analog of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention may be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • WO 01/46145, WO 01/46146, WO 2005/121087, WO 2007/042295 WO 2008/127188 and WO 2008/155357 all describe substituted 4-phenyl-N-alkyl-piperazines and 4-phenyl-N-alkyl-piperidines, reported to be modulators of dopamine neurotransmission, and to be useful in treatment of symptoms of various disorders of the central nervous system.
  • the deuterated analog of the invention is considered useful for the same medical indications as described in these publications, and these publications therefore are incorporated by reference.
  • Neurological indications contemplated according to these publications include the treatment of Huntington's disease and other movement disorders, as well as movement disorders induced by drugs.
  • the invention relates to the use of the deuterated analog of the invention for use as a medicament for the treatment of Huntington's disease.
  • the invention provides deuterated analogs for use as medicaments. Therefore, in another aspect, the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the compound of the invention.
  • a deuterated analog of the invention for use in therapy may be administered in the form of the raw compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • compositions of the invention may in particular be formulated as described in WO 01/46145.
  • the dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • compositions containing of from about 1 to about 500 mg of active ingredient per individual dose, preferably of from about 10 to about 100 mg, most preferred of from about 25 to about 50 mg, are suitable for therapeutic treatments.
  • the daily dose will preferably be administered in individual dosages 1 to 4 times daily.
  • the invention provides a method for the treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the deuterated analog of the invention.
  • the dopamine mediated disorder is Huntington's disease.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease.
In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.

Description

    FIELD OF THE INVENTION
  • The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease.
  • In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.
    • BACKGROUND OF THE INVENTION
  • Deuterium, also called “heavy hydrogen”, is a stable isotope of hydrogen with a natural abundance in the oceans of Earth of approximately one atom in 6,500 of hydrogen (˜154 ppm). Deuterium thus accounts for approximately 0.0154% (alternately, on a mass basis: 0.0308%) of all naturally occurring hydrogen in the oceans on Earth. The nucleus of deuterium, called a deuteron, contains one proton and one neutron, whereas the hydrogen nucleus contains no neutron.
  • Deuterium forms bonds with carbon that vibrate at a lower frequency and are thus stronger than C—H bonds. Therefore “heavy hydrogen” versions of drugs may be more stable towards degradation and last longer in the organism. Incorporating deuterium in place of hydrogen thus may improve the pharmacodynamic and pharmacokinetic profiles of drugs, thus modifying the metabolic fate, while retaining the pharmacologic activity and selectivity of physiologically active compounds. Deuterated drugs thus may positively impact safety, efficacy and/or tolerability.
  • Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine, a dopaminergic stabilizer currently in clinical development for the treatment of Huntington's disease. The compound is described in e.g. WO 01/46145, and in e.g. WO 2006/040155 an alternative method for its synthesis is described.
    • SUMMARY OF THE INVENTION
  • The object of the present invention is to provide analogs of Pridopidine with improved pharmacodynamic and pharmacokinetic profiles.
  • Therefore, in its first aspect the invention provides a partially or fully deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine as represented by Formula 1, below.
  • In another aspect the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine of the invention, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • Viewed from another aspect the invention relates to the use of the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine of the invention as a medicament, or for the manufacture of a medicament.
  • In a further aspect the invention provides a method for treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine according to the invention, or a pharmaceutically acceptable salt thereof.
  • Other aspects of the invention will be apparent to the person skilled in the art from the following detailed description and examples.
    • DETAILED DESCRIPTION OF THE INVENTION Deuterated Analogs of Pridopidine
  • In its first aspect the present invention provides deuterated analogs of Pridopidine. The deuterated analog of the invention may be a fully or partially deuterium substituted derivative. The deuterated analog of the invention may in particular be characterised by Formula I
  • Figure US20130197031A1-20130801-C00001
  • or a pharmaceutically acceptable salt thereof, wherein
  • at least one of R1-R23 represents deuterium (D); and
  • the remaining of R1-R23 represent hydrogen (H).
  • In the context of this invention, when a particular position is designated as holding deuterium, it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015%.
  • In a preferred embodiment the abundance of deuterium at that position is at least 3340 times greater (i.e. at least 50.1% incorporation of deuterium) than the natural abundance of deuterium. In other preferred embodiments of the invention the abundance of deuterium at that position is at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • In a preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R1-R2 represent deuterium (D); and
  • all of R3-R23 represent hydrogen (H).
  • In another preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • at least one of R1-R7 represents deuterium (D); and
  • the remaining of R1-R23 represent hydrogen (H).
  • In a third preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • all of R1-R7 represent deuterium (D); and
  • all of R8-R23 represent hydrogen (H).
  • In a fourth preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R8, R9, R10 and R11 represent deuterium (D); and
  • all of R1-R7 and R12-R23 represent hydrogen (H).
  • In a fifth preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R12 represents deuterium (D); and
  • all of R1-R11 and R13-R23 represent hydrogen (H).
  • In a sixth preferred embodiment the deuterated analog of the invention is a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein
  • R17-R20 represent deuterium (D); and
  • all of R1-R16 and R21-R23 represent hydrogen (H).
  • Any combination of two or more of the embodiments described herein is considered within the scope of the present invention.
    • Pharmaceutically Acceptable Salts
  • The deuterated analog of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the deuterated analog of the invention.
  • Examples of pharmaceutically acceptable salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate, the toluene-p-sulphonate, and the like. Such salts may be formed by procedures well known and described in the art.
  • Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a deuterated analog of the invention and its pharmaceutically acceptable acid addition salt.
  • Examples of pharmaceutically acceptable cationic salts of a deuterated analog of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a deuterated analog of the invention containing an anionic group. Such cationic salts may be formed by procedures well known and described in the art.
  • The deuterated analog of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
    • Methods of Preparation
  • The deuterated analog of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples. The starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • Also one compound of the invention may be converted to another compound of the invention using conventional methods.
  • The end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
    • Biological Activity
  • WO 01/46145, WO 01/46146, WO 2005/121087, WO 2007/042295 WO 2008/127188 and WO 2008/155357 all describe substituted 4-phenyl-N-alkyl-piperazines and 4-phenyl-N-alkyl-piperidines, reported to be modulators of dopamine neurotransmission, and to be useful in treatment of symptoms of various disorders of the central nervous system. The deuterated analog of the invention is considered useful for the same medical indications as described in these publications, and these publications therefore are incorporated by reference.
  • Neurological indications contemplated according to these publications include the treatment of Huntington's disease and other movement disorders, as well as movement disorders induced by drugs.
  • Therefore, in a preferred embodiment, the invention relates to the use of the deuterated analog of the invention for use as a medicament for the treatment of Huntington's disease.
    • Pharmaceutical Compositions
  • Viewed from another aspect the invention provides deuterated analogs for use as medicaments. Therefore, in another aspect, the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the compound of the invention.
  • While a deuterated analog of the invention for use in therapy may be administered in the form of the raw compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • Pharmaceutical compositions of the invention may in particular be formulated as described in WO 01/46145.
  • Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).
  • The dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • The actual dosage depends on the nature and severity of the disease being treated, and is within the discretion of the physician, and may be varied by titration of the dosage to the particular circumstances of this invention to produce the desired therapeutic effect. However, it is presently contemplated that pharmaceutical compositions containing of from about 1 to about 500 mg of active ingredient per individual dose, preferably of from about 10 to about 100 mg, most preferred of from about 25 to about 50 mg, are suitable for therapeutic treatments. The daily dose will preferably be administered in individual dosages 1 to 4 times daily.
    • Methods of Therapy
  • In another aspect the invention provides a method for the treatment, prevention or alleviation of a dopamine mediated disorder of a living animal body, including a human, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the deuterated analog of the invention.
  • In a preferred embodiment the dopamine mediated disorder is Huntington's disease.
    • EXAMPLES
  • The invention is further illustrated in the examples below, which in no way are intended to limit the scope of the invention.
    • Example 1 Preparatory Example
  • 4-(3-Methanesulfonyl-phenyl)-1-propyl-d7-piperidine x HCl
  • 4-(3-Methanesulfonyl-phenyl)-piperidine (0.43 g), CH3CN (4 ml), K2CO3 (0.49 g), and 1-lodopropane-d7 (0.19 g) are mixed and heated in microwave oven for 30 min at 120° C. The mixture is filtered and evaporated to dryness and purified on silica column using iso-octane:EtOAc (1:1) containing 5% NEt3 as eluent. After evaporation of the fractions with pure product, the residue is re-dissolved in EtOAc and washed with a 10% Na2CO3 solution. The organic phase is separated and dried with Na2SO4, filtered and evaporated to yield pure product (0.33 g). The amine is then converted to the HCl salt, and re-crystallized from EtOH:Et2O. M.p. 198-199° C.

Claims (22)

1. A fully or partially deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine represented by Formula 1
Figure US20130197031A1-20130801-C00002
or a pharmaceutically acceptable salt thereof, wherein at least one of R1-R21 represents deuterium (D); and the remaining of R1-R23 represent hydrogen (H).
2. The deuterated analog or pharmaceutically acceptable salt thereof according to claim 1, wherein
R1-R2 represent deuterium (D); and
all of R1-R23 represent hydrogen (H); or
at least one of R1-R7 represents deuterium (D); and
the remaining of R1-R23 represent hydrogen (H); or
all of R1-R7 represent deuterium (D); and
all of R8-R2 represent hydrogen (H); or
R8, R9, R10 and R11 represent deuterium (D); and
all of R1-R7 and R12-R23 represent hydrogen (H); or
R12 represents deuterium (D); and
all of R1-R11 and R13-R23 represent hydrogen (H); or
R17-R20 represent deuterium (D); and
all of R1-R16 and R21-R23 represent hydrogen (H).
3-7. (canceled)
8. A pharmaceutical composition which comprises a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof according to claim 1, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
9-10. (canceled)
11. A method for treatment, prevention or alleviation of a dopamine mediated disorder of a living animal which comprises administering to such a living animal body a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof according to claim 1.
12. A pharmaceutical composition which comprises a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof according to claim 2 together with at least one pharmaceutically acceptable carrier, excipient or diluent.
13. A method for treatment, prevention or alleviation of a dopamine mediated disorder of a living animal which comprises administering to such a living animal body a therapeutically effective amount of a deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof according to claim 2.
14. The deuterated analog or pharmaceutically acceptable salt thereof according to claim 2, wherein
R1-R2 represent deuterium (D); and
all of R3-R23 represent hydrogen (H).
15. The deuterated analog or pharmaceutically acceptable salt thereof according to claim 2, wherein
at least one of R1-R7 represents deuterium (D); and
the remaining of R1-R23 represent hydrogen (H).
16. The deuterated analog or pharmaceutically acceptable salt thereof according to claim 2, wherein
all of R1-R7 represent deuterium (D); and
all of R8-R23 represent hydrogen (H).
17. The deuterated analog or pharmaceutically acceptable salt thereof according to claim 2, wherein
R8, R9, R10 and R11 represent deuterium (D); and
all of R1-R7 and R12-R23 represent hydrogen (H).
18. The deuterated analog or pharmaceutically acceptable salt thereof according to claim 2, wherein
R12 represents deuterium (D); and
all of R1-R11 and R13-R23 represent hydrogen (H).
19. The deuterated analog or pharmaceutically acceptable salt thereof according to claim 2, wherein
R17-R20 represent deuterium (D); and
all of R1-R16 and R21-R23 represent hydrogen (H).
20. A pharmaceutical composition according to claim 12, wherein in the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof,
R1-R2 represent deuterium (D); and
all of R3-R23 represent hydrogen (H).
21. A pharmaceutical composition according to claim 12, wherein in the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof,
at least one of R1-R7 represents deuterium (D); and
the remaining of R1-R23 represent hydrogen (H).
22. A pharmaceutical composition according to claim 12, wherein in the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof,
all of R1-R7 represent deuterium (D); and
all of R8-R23 represent hydrogen (H).
23. A pharmaceutical composition according to claim 12, wherein in the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof,
R8, R9, R10 and R11 represent deuterium (D); and
all of R1-R7 and R12-R23 represent hydrogen (H).
24. A pharmaceutical composition according to claim 12, wherein in the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1 -propyl-piperidine or a pharmaceutically acceptable salt thereof,
R12 represents deuterium (D); and
all of R1-R11 and R13-R23 represent hydrogen (H).
25. A pharmaceutical composition according to claim 12, wherein in the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof,
R17-R20 represent deuterium (D); and
all of R1-R16 and R21-R23 represent hydrogen (H).
26. A method according to claim 13, wherein in the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof,
R1-R2 represent deuterium (D); and
all of R3-R23 represent hydrogen (H).
27. A method according to claim 13, wherein in the deuterated analog of 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine or a pharmaceutically acceptable salt thereof,
at least one of R1-R7 represents deuterium (D); and
the remaining of R1-R23 represent hydrogen (H).
US13/820,024 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers Abandoned US20130197031A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201070385 2010-09-03
DKPA201070385 2010-09-03
PCT/EP2011/064954 WO2012028635A1 (en) 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/064954 A-371-Of-International WO2012028635A1 (en) 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/968,522 Continuation US20160166559A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US14/968,510 Continuation US20160095847A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Publications (1)

Publication Number Publication Date
US20130197031A1 true US20130197031A1 (en) 2013-08-01

Family

ID=44653278

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/820,024 Abandoned US20130197031A1 (en) 2010-09-03 2011-08-31 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US14/968,510 Abandoned US20160095847A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US14/968,522 Abandoned US20160166559A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US15/960,041 Abandoned US20180235950A1 (en) 2010-09-03 2018-04-23 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US16/133,192 Active US10799492B2 (en) 2010-09-03 2018-09-17 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/968,510 Abandoned US20160095847A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US14/968,522 Abandoned US20160166559A1 (en) 2010-09-03 2015-12-14 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US15/960,041 Abandoned US20180235950A1 (en) 2010-09-03 2018-04-23 Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US16/133,192 Active US10799492B2 (en) 2010-09-03 2018-09-17 Deuterated analogs of pridopidine useful as dopaminergic stabilizers

Country Status (18)

Country Link
US (5) US20130197031A1 (en)
EP (1) EP2611759A1 (en)
JP (1) JP2013536825A (en)
KR (1) KR20140008297A (en)
CN (1) CN103249697B (en)
AU (2) AU2011298382A1 (en)
BR (1) BR112013005125A2 (en)
CA (1) CA2810092A1 (en)
CL (1) CL2013000604A1 (en)
EA (1) EA201390332A1 (en)
IL (1) IL224776A (en)
MX (1) MX2013002453A (en)
NZ (1) NZ608120A (en)
PE (1) PE20140105A1 (en)
PH (1) PH12013500406A1 (en)
SG (2) SG10201506761XA (en)
WO (1) WO2012028635A1 (en)
ZA (1) ZA201301902B (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105736A1 (en) * 2007-04-12 2010-04-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US9006445B2 (en) 2011-09-07 2015-04-14 IVAX International GmbH Polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US20160095847A1 (en) * 2010-09-03 2016-04-07 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2017015609A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Process for preparing pridopidine
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2018039477A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating functional decline
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
WO2018053280A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating rett syndrome
WO2018053287A1 (en) 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
WO2018136600A1 (en) 2017-01-20 2018-07-26 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of fragile x syndrome
US10130621B2 (en) 2014-06-30 2018-11-20 Teva Pharmaceutical Industries Ltd. Analogs of pridopidine, their preparation and use
WO2019036358A1 (en) 2017-08-14 2019-02-21 Teva Pharmaceuticals International Gmbh Method of treating amyotrophic lateral sclerosis with pridopidine
WO2019046568A1 (en) 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh High copncentration dosage forms of pridopidine
WO2019050775A1 (en) 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh Pridopidine for treating drug induced dyskinesias
US10322119B2 (en) 2013-06-21 2019-06-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating Huntington's disease
US10959996B2 (en) 2015-03-06 2021-03-30 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2021161319A1 (en) 2020-02-13 2021-08-19 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
WO2021224914A1 (en) 2020-05-04 2021-11-11 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective s1r agonist
US11207308B2 (en) 2012-04-04 2021-12-28 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US11666566B2 (en) 2012-09-18 2023-06-06 Auspex Pharmaceuticals, Inc. Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016010213A (en) 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Novel pharmaceutical formulations.
PL3261721T3 (en) 2015-02-25 2022-12-27 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve memory
US10459055B2 (en) * 2017-04-07 2019-10-29 Case Western Reserve University System and method for reduced field of view MR fingerprinting for parametric mapping
JP2023526439A (en) * 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド Cyclodeuterated gaboxadol and its use for the treatment of psychiatric disorders
EP4153111A4 (en) 2020-05-20 2024-06-12 Nthalmic Holding Pty Ltd METHOD AND APPARATUS FOR MANAGING MEIBOMIAN GLAND DEFICIENCY

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6603008B1 (en) * 1999-12-03 2003-08-05 Pfizer Inc. Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
US6903120B2 (en) * 1999-12-22 2005-06-07 A. Carlsson Research Ab Modulators of dopamine neurotransmission
US20070082929A1 (en) * 2005-10-06 2007-04-12 Gant Thomas G Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties
US20070197695A1 (en) * 2006-02-10 2007-08-23 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US7517990B2 (en) * 2002-11-15 2009-04-14 Wako Pure Chemical Industries, Ltd. Method for deuteration of a heterocyclic ring
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
US8288414B2 (en) * 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (en) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
DE10123129A1 (en) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds
US7004629B2 (en) 2003-07-26 2006-02-28 Arthur Joseph Shrader Method and apparatus for hanging a resealable bag
EP1768958B1 (en) 2004-06-08 2009-11-18 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
JP4891908B2 (en) 2004-10-13 2012-03-07 エヌエスエービー，フィリアル アフ ニューロサーチ スウェーデン アクチボラゲット，スヴェリエ Method for synthesizing 4- (3-methanesulfonylphenyl) -1-n-propylpiperidine
SE529246C2 (en) 2005-10-13 2007-06-12 Neurosearch Sweden Ab New disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
AU2006315684A1 (en) 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
CN101360742A (en) * 2005-11-14 2009-02-04 奥斯拜客斯制药有限公司 Substituted phenylpiperidines with serotonin-derived activity and enhanced therapeutic properties
PT2146961E (en) 2007-04-12 2014-04-30 Ivax Int Gmbh N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
ES2528040T3 (en) 2007-06-18 2015-02-03 A.Carlsson Research Ab Use of dopamine stabilizers
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9006445B2 (en) 2011-09-07 2015-04-14 IVAX International GmbH Polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
NZ630560A (en) 2012-04-04 2016-11-25 Teva Pharmaceuticals Int Gmbh Pharmaceutical compositions for combination therapy
EP2900226A4 (en) 2012-09-27 2016-03-30 Teva Pharma Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
CA2884781A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
ES2879631T3 (en) 2013-06-21 2021-11-22 Prilenia Neurotherapeutics Ltd Pridopidine for the treatment of Huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20161220A1 (en) 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh MODIFIED RELEASE PRIDOPIDINE FORMULATIONS
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
PL3261721T3 (en) 2015-02-25 2022-12-27 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve memory
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (en) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh PROCESS TO PREPARE PRIDOPIDINE
US20170026730A1 (en) 2015-07-23 2017-01-26 Knowles Electronics, Llc Microphone with temperature sensor
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
PT3504187T (en) 2016-08-24 2025-05-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
DK3503890T3 (en) 2016-08-24 2025-01-27 Prilenia Neurotherapeutics Ltd USE OF PRIDOPIDINE FOR THE TREATMENT OF DYSTONIAS
CN109952100A (en) 2016-09-15 2019-06-28 普瑞尼亚医疗发展有限公司 Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
BR112019005178A2 (en) 2016-09-16 2019-07-02 Cargill Inc genetically modified yeast, and process for producing ethanol.
IL268125B2 (en) 2017-01-20 2023-04-01 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of fragile x syndrome
ES2938546T3 (en) 2017-08-14 2023-04-12 Prilenia Neurotherapeutics Ltd Treatment method of amyotrophic lateral sclerosis with pridopidine
NL2019473B1 (en) 2017-09-01 2019-03-11 Isobionics B V Terpene Synthase producing patchoulol and elemol, and preferably also pogostol
CN111343982A (en) 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 Pridopidine for the treatment of drug-induced dyskinesia

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US6603008B1 (en) * 1999-12-03 2003-08-05 Pfizer Inc. Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
US6903120B2 (en) * 1999-12-22 2005-06-07 A. Carlsson Research Ab Modulators of dopamine neurotransmission
US7517990B2 (en) * 2002-11-15 2009-04-14 Wako Pure Chemical Industries, Ltd. Method for deuteration of a heterocyclic ring
US20070082929A1 (en) * 2005-10-06 2007-04-12 Gant Thomas G Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties
US20070197695A1 (en) * 2006-02-10 2007-08-23 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
US8288414B2 (en) * 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Baillie, Pharmacology Rev. 33: 81-132 (1981) *
Browne et al. "Stable isotope ..... " Journal of Clinical Pharmacology" (38), 213-220 (1998) *
Cherrah, Biomedical and Environmental Mass Spectrometry Volume 14 Issue 11, Pages 653 - 657 (1987) *
Dyck et al. "Effect of deuterium ....." J. Neurochem. v.46(2) 399-404 (1986) *
Dyhring et al. "The dopaminergic......" Eur. J. Pharm. 628, p.19-26 (2010) *
Gouyette, Biomedical And Environmental Mass Spectrometry, Vol. 15, 243-247 (1988) *
Haskins el al. "The application of stable isotopes......" Biomedical Spectrometry 9 (7), 269-277, (1982) *
Hellden et al. "The dopaminergic....." Eur. J. Pharmacol. 68, p.1281-1286 (2012) *
Honma et al., Drug Metab Dispos 15 (4): 551 (1987) *
Pieniaszek, J Clin Pharmacol. 39:817-825 (1999) *
Tonn et al. " simultaneous analysis....." Biological Mass Spectrometry 22 (11) 633-642, (1993) *
Waters et al."substituted 4-phenyl....." CA155:399294 (2011) *
Wienkers et al. "Multiple cytochrome....." Drug met. disposition v.30(12) 1372-1377 (2002) *
Wolen et al. "Application of stable isotope......" Journal of Clinical Pharmacology (26), 419-424 (1986) *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
US9139525B2 (en) 2007-04-12 2015-09-22 Teva Pharmaceuticals International Gmbh N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US20100105736A1 (en) * 2007-04-12 2010-04-29 Nsab, Filial Af Neurosearch Sweden Ab, Sverige N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US20160095847A1 (en) * 2010-09-03 2016-04-07 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US10799492B2 (en) 2010-09-03 2020-10-13 Prilenia Neurotherapeutics Ltd. Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9006445B2 (en) 2011-09-07 2015-04-14 IVAX International GmbH Polymorphic form of pridopidine hydrochloride
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US9814706B2 (en) 2011-12-08 2017-11-14 Teva Pharmaceuticals International Gmbh Hydrobromide salt of pridopidine
US11207308B2 (en) 2012-04-04 2021-12-28 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
US11666566B2 (en) 2012-09-18 2023-06-06 Auspex Pharmaceuticals, Inc. Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
US10322119B2 (en) 2013-06-21 2019-06-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating Huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US12390456B2 (en) 2013-06-21 2025-08-19 Prilenia Neurotherapeutics Ltd. Pridopidine for treating Huntington's disease
US11141412B2 (en) 2014-06-30 2021-10-12 Prilenia Neurotherapeutics Ltd. Analogs of pridopidine, their preparation and use
US10130621B2 (en) 2014-06-30 2018-11-20 Teva Pharmaceutical Industries Ltd. Analogs of pridopidine, their preparation and use
US10406145B2 (en) 2014-06-30 2019-09-10 Prilenia Neurotherapeutics Ltd. Analogs of pridopidine, their preparation and use
US9796673B2 (en) 2014-12-22 2017-10-24 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US11564917B2 (en) 2015-03-06 2023-01-31 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
US11446291B2 (en) 2015-03-06 2022-09-20 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
US12016858B2 (en) 2015-03-06 2024-06-25 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
US10959996B2 (en) 2015-03-06 2021-03-30 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
US11648244B2 (en) 2015-03-06 2023-05-16 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
US11357772B2 (en) 2015-03-06 2022-06-14 Auspex Pharmaceuticals, Inc. Methods for the treatment of abnormal involuntary movement disorders
WO2017015609A1 (en) * 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Process for preparing pridopidine
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
EP4516356A2 (en) 2016-08-24 2025-03-05 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
WO2018039477A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating functional decline
US11207310B2 (en) 2016-08-24 2021-12-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
US11826361B2 (en) 2016-08-24 2023-11-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
WO2018053287A1 (en) 2016-09-15 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of anxiety and depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
EP4005570A1 (en) 2016-09-16 2022-06-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
WO2018053280A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating rett syndrome
US11234973B2 (en) 2017-01-20 2022-02-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile X syndrome
WO2018136600A1 (en) 2017-01-20 2018-07-26 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of fragile x syndrome
EP4620471A2 (en) 2017-08-14 2025-09-24 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
EP4154882A1 (en) 2017-08-14 2023-03-29 Prilenia Neurotherapeutics Ltd. Treating amyotrophic lateral sclerosis with pridopidine
US11406625B2 (en) 2017-08-14 2022-08-09 Prilenia Neurotherapeutics Ltd. Method of treating amyotrophic lateral sclerosis with pridopidine
WO2019036358A1 (en) 2017-08-14 2019-02-21 Teva Pharmaceuticals International Gmbh Method of treating amyotrophic lateral sclerosis with pridopidine
US11452694B2 (en) 2017-08-30 2022-09-27 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
WO2019046568A1 (en) 2017-08-30 2019-03-07 Teva Pharmaceuticals International Gmbh High copncentration dosage forms of pridopidine
WO2019050775A1 (en) 2017-09-08 2019-03-14 Teva Pharmaceuticals International Gmbh Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US11000519B2 (en) 2017-09-08 2021-05-11 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
WO2021161319A1 (en) 2020-02-13 2021-08-19 Prilenia Neurotherapeutics Ltd. Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
WO2021224914A1 (en) 2020-05-04 2021-11-11 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective s1r agonist

Also Published As

Publication number Publication date
WO2012028635A1 (en) 2012-03-08
JP2013536825A (en) 2013-09-26
SG188298A1 (en) 2013-04-30
US20160095847A1 (en) 2016-04-07
NZ608120A (en) 2014-12-24
US10799492B2 (en) 2020-10-13
US20190015401A1 (en) 2019-01-17
SG10201506761XA (en) 2015-10-29
EA201390332A1 (en) 2013-08-30
AU2016250390A1 (en) 2016-11-10
CA2810092A1 (en) 2012-03-08
EP2611759A1 (en) 2013-07-10
ZA201301902B (en) 2014-05-28
KR20140008297A (en) 2014-01-21
PE20140105A1 (en) 2014-02-14
IL224776A (en) 2017-07-31
CN103249697B (en) 2016-06-15
US20180235950A1 (en) 2018-08-23
PH12013500406A1 (en) 2019-07-17
BR112013005125A2 (en) 2016-08-16
CL2013000604A1 (en) 2013-11-15
AU2011298382A1 (en) 2013-05-02
MX2013002453A (en) 2013-08-01
CN103249697A (en) 2013-08-14
US20160166559A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
US10799492B2 (en) Deuterated analogs of pridopidine useful as dopaminergic stabilizers
AU2014292722B2 (en) Quinine compounds, and optical isomers, preparation method and medical use thereof
US10280158B2 (en) Immune adjustment compound, use thereof and pharmaceutical composition comprising same
JP2001524954A (en) Similar compounds of cocaine
JP2015510916A (en) Use of pyrazole derivatives in the treatment of acute exacerbations of chronic obstructive pulmonary disease
CN102140079B (en) Novel yunaconitine and preparation method thereof as well as pharmaceutical composition based on compound as active ingredient and application of novel yunaconitine
JP2010514734A (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
US9457018B2 (en) Method for combating adverse effects arising from antipsychotic treatment
JP2008179541A (en) Neuropathic pain treatment
JPH0269417A (en) Schizophrenia treatment composition
WO2015048821A1 (en) Tricyclic pyrone compounds reduce amyloid beta aggregates
US9125916B2 (en) Methods of treating hypertrophic cardiomyopathy
US8168632B2 (en) Bicyclic amide derivatives for the treatment of respiratory disorders
CN101402633A (en) Benzamide derivatives, preparation method and medical uses thereof
US9745275B2 (en) Pain-related compound and medical composition
US20250115596A1 (en) Esters of 8-methyl-8-azabicyclo[3.2.1] octan-3-yl 3-hydroxy-2-phenylpropanoate
JP2005060311A (en) Neuropathic pain therapeutic agent comprising N- (benzoyl) amino acid derivative as an active ingredient
KR101172472B1 (en) Quaternary ammonium compound, process for producing the same, therapeutic agent for cerebrovascular disorder, and therapeutic agent for heart disease
JP3681770B2 (en) Treatment for senile dementia or Alzheimer's disease
US10759822B2 (en) Brain-targeting prodrug for AMPA receptor synergist, and pharmaceutical applications thereof
JP4888751B2 (en) Trifluoropropylaminopentane derivative and method for producing the same
WO2012070601A1 (en) Novel 2-alkynyl-n9-propargyladenine and medicinal use thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: IVAX INTERNATIONAL GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE;REEL/FRAME:029975/0139

Effective date: 20121025

AS Assignment

Owner name: NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE, DE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SONESSON, CLAS;REEL/FRAME:030187/0684

Effective date: 20130314

AS Assignment

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH, SWITZERLA

Free format text: CHANGE OF NAME;ASSIGNOR:IVAX INTERNATIONAL GMBH;REEL/FRAME:035318/0079

Effective date: 20150223

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION